TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change from Baseline on Visual Analogue Scale for Drug Liking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from Baseline on Visual Analogue Scale for Drug High
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptance of arm rehabilitation robot therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Influence on motivation through visual feedback
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Adherence to study diet
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Abundance of metabolites in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Abundance of metabolites in stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in child Iron deficiency anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in children Vitamin A status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in children Zinc status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of SARS-CoV-2 infection
Endpoint domain: Adverse events/effects
Primary endpoint: Hepcidin / ferritin plasma ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Composite motor score changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of major adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Waste and Hip Circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Fugl-Meyer Assessment Scale for upper extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily individual exposure estimates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Paresthesia Distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximum Severity of Flushing Events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of DBS responders exhibiting RR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adherence to antipsychotic medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants With Acute Graft-versus-host Disease (aGVHD)
Endpoint domain: Adverse events/effects
Primary endpoint: Changes of hematoma volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Delayed peri-hemorrhage edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes of PA/RBP/TRSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Local Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: seven-day point prevalence abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent Change in ERK Phosphorylation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of patients with clinical relapse of VVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in 2-hour blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: response rate for patients with relapsed or refractory acute lymphoblastic leukemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: adverse events after brief, high intensity chemotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Antimicrobial peptide levels of LL-37
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety of Balloon Implant
Endpoint domain: Adverse events/effects
Primary endpoint: Nocturnal systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: level of disialotransferrin in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: level of ethyl glucuronide in hair
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall number of adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients Who Achieve Adequate Sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Tolerability of VE303
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: biochemistry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urine analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: vital sign
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Size of Geographic Atrophy Lesion Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cycle exercise endurance time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events during the first 24 hours and up to 30 days
Endpoint domain: Adverse events/effects
Primary endpoint: Change in functional fitness
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence rate of specific serious adverse events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Complete Response Rate (CR+CRu)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of pictures named correctly
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: FR assessed by the ccNexfin system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from baseline Muscular Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes from baseline Corporal Water
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the use of post-operative narcotics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Tricuspid anular plane systolic excursion (TAPSE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of SCD patients meeting high user criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in clinical performance indicators
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient and clinician outcome measures
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Facial skin hydration change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Facial skin elasticity change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Subjects With Major Adverse Cardiovascular Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Subjects With Major Adverse Cardiovascular Event or Hospitalization for Unstable Angina That Led to Urgent Coronary Revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical Pregnancy per cycle of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: metabolic patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number and severity of participants with overt hepatic encephalopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Ki 67 Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Correlation coefficient between ORI and PaO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Five Times Sit-to-stand (5XSTS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Participating in Cardiac Rehabilitation Programs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Subjects Who Had an Additional Hernia Occur
Endpoint domain: Adverse events/effects
Primary endpoint: Depression (PHQ-9 Instrument)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Child Strength and Difficulties Questionnaire (SDQ) Total Difficulties (TD) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Nature of dose limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Oucher pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of initial low-dose CT scan screenings
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percent Change From Baseline in Erosion Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Frequency of Solicited Local and Systemic Adverse Reactions (ARs)
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of Unsolicited Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline in Geometric Mean Titer (GMT) of Serum Neutralizing Anti-CMV Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Forced Expiratory Volume in the First Second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Radiation Exposure Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: structural or functional change of the heart
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Role of social media
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Short Musculoskeletal Function Assessment (SMFA) Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Kellgren-Lawrence grading system for osteoarthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: American Orthopaedic Foot and Ankle Score (AOFAS) Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Increase in brain extracellular lactate, pyruvate and glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of undiagnosed pre-diabetes or undiagnosed diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Patients Requiring Supplemental Oxygen Beyond 8L Nasal Cannula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Fried frailty criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Filial Responsibility Scale-Youth
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Hot flash distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Neutrophile activation assessed by free DNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of patients with abnormal Jitter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of patients surviving without disease progression
Endpoint domain: Mortality/survival
Primary endpoint: impulsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: distractibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of irinotecan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cholesterol Efflux Capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pharmacokinetics of metformin in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Study Participants With Skin Reactions Less Than 10%
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with confirmed diagnosis of Cystinosis
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants with confirmed diagnosis of SMA
Endpoint domain: Mortality/survival
Primary endpoint: Change from Baseline in ADAS-Cog total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Subjects With Serious Adverse Events (SAEs) and Related SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity and specificity of FFRCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity and Frequency of Hallucinations
Endpoint domain: Adverse events/effects
Primary endpoint: Overall Visual Analog Scale score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intensity of asthenia
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Mean change in coronal CT score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of lymphedema development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Time to lymphedema development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: AUC 0-10
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC GIR 0-12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in esophageal motility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Correlation of ctDNA analysis with radiologic tumor assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Accuracy of EUS-guided nCLE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PPPASI total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: ETF tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of doripenem in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in VISA-A Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change of Patient Rated Pruritus Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cooperation in Pediatric dentistry
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Type of Chronic Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: A-a Gradient at End Exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve cTnT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Duration of arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cumulative vasopressor index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of Acute Grade 3/4 Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients With Acute Grade 3/4 Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Weight Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Psychological Change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in resting-state fMRI BOLD signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Average AHI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Primary Graft Dysfunction (PGD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Background Parenchymal Uptake (BPU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Gastroesophageal reflux disease symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Definitive Cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: arterial flow through the tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Total Preference Composite Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change From Baseline in Regimen Attributes Composite Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pretest and Posttest scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stage distribution of nasopharyngeal carcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Side branch region ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Number of Child Utterances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-reported sleep quality
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Bronchial inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Usability of the intervention
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of times having to communicate a bad news in the last year
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self-evaluation of the skills in breaking bad news and their self-perceived quality
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of Serious Adverse Events including major Hypoglycaemia
Endpoint domain: Adverse events/effects
Primary endpoint: Mean total hours of awake time in the OFF state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Cognitive outcome
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proportion of patients completing protocol therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Degree of anterior movement of the maxilla
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Clarity of Image and ease of interpretation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Shoulder Pain and Disability Index (Change)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: first occurrence of intensive care unit admission
Endpoint domain: Mortality/survival
Primary endpoint: first occurrence of mechanical ventilation
Endpoint domain: Mortality/survival
Primary endpoint: Anti-tumor activity of ABI-007
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Invasive gradient (mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety as assessed by laboratory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety as assessed by vital sign measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Digestive health as assessed by GSRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Bowel movements and stool consistency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Nutrient uptake as determined by serum levels of albumin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ischemic myocardial injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bronchial Inflammation in sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Humphrey Field Analyzer (HFA) total point score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Grade of inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression in training loads (kg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Gastrointestinal (GI) Module of the Pediatric Quality of Life Inventory (PedsQL)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Clotting of the dialysis session
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: rates of cardioversion of atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Nugent score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Menstrual changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early detection of minimal metastatic disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: rate of (serious) adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Objectively measured adherence
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to lose skin sensation (light touch and thermal) over the injection site
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes